IQVIA (IQV) Competitors

$170.68 -1.70 (-0.99%)

Closing price 03:59 PM Eastern

Extended Trading

$170.70 +0.03 (+0.02%)

As of 04:21 PM Eastern

IQV vs. BRKR, ICLR, MEDP, TECH, and A

Should you buy IQVIA stock or one of its competitors? MarketBeat compares IQVIA with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with IQVIA include Bruker (BRKR), Icon (ICLR), Medpace (MEDP), Bio-Techne (TECH), and Agilent Technologies (A).

How does IQVIA compare to Bruker?

Bruker (NASDAQ:BRKR) and IQVIA (NYSE:IQV) are related companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, media sentiment, valuation and risk.

IQVIA has a net margin of 8.33% compared to Bruker's net margin of -0.65%. IQVIA's return on equity of 30.50% beat Bruker's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bruker	-0.65%	11.60%	4.25%
IQVIA	8.33%	30.50%	6.53%

Bruker has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market. Comparatively, IQVIA has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market.

Bruker presently has a consensus price target of $50.54, suggesting a potential upside of 14.44%. IQVIA has a consensus price target of $225.69, suggesting a potential upside of 32.23%. Given IQVIA's stronger consensus rating and higher possible upside, analysts plainly believe IQVIA is more favorable than Bruker.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bruker	2 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.47
IQVIA	0 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, IQVIA had 8 more articles in the media than Bruker. MarketBeat recorded 18 mentions for IQVIA and 10 mentions for Bruker. IQVIA's average media sentiment score of 0.98 beat Bruker's score of 0.66 indicating that IQVIA is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bruker	2 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
IQVIA	10 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

79.5% of Bruker shares are owned by institutional investors. Comparatively, 89.6% of IQVIA shares are owned by institutional investors. 27.2% of Bruker shares are owned by insiders. Comparatively, 1.7% of IQVIA shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

IQVIA has higher revenue and earnings than Bruker. Bruker is trading at a lower price-to-earnings ratio than IQVIA, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bruker	$3.46B	1.94	-$8.60M	-$0.24	N/A
IQVIA	$16.63B	1.71	$1.36B	$8.07	21.15

Summary

IQVIA beats Bruker on 15 of the 17 factors compared between the two stocks.

How does IQVIA compare to Icon?

IQVIA (NYSE:IQV) and Icon (NASDAQ:ICLR) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk, media sentiment and valuation.

IQVIA has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market. Comparatively, Icon has a beta of 1.23, suggesting that its stock price is 23% more volatile than the broader market.

IQVIA has a net margin of 8.33% compared to Icon's net margin of 7.40%. IQVIA's return on equity of 30.50% beat Icon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IQVIA	8.33%	30.50%	6.53%
Icon	7.40%	10.58%	6.01%

89.6% of IQVIA shares are owned by institutional investors. Comparatively, 95.6% of Icon shares are owned by institutional investors. 1.7% of IQVIA shares are owned by company insiders. Comparatively, 44.0% of Icon shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

IQVIA currently has a consensus price target of $225.69, indicating a potential upside of 32.23%. Icon has a consensus price target of $149.38, indicating a potential upside of 27.58%. Given IQVIA's stronger consensus rating and higher possible upside, equities research analysts plainly believe IQVIA is more favorable than Icon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IQVIA	0 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	3.00
Icon	3 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.27

IQVIA has higher revenue and earnings than Icon. Icon is trading at a lower price-to-earnings ratio than IQVIA, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IQVIA	$16.63B	1.71	$1.36B	$8.07	21.15
Icon	$8.28B	1.14	$791.47M	$7.39	15.84

In the previous week, IQVIA had 12 more articles in the media than Icon. MarketBeat recorded 18 mentions for IQVIA and 6 mentions for Icon. IQVIA's average media sentiment score of 0.98 beat Icon's score of 0.96 indicating that IQVIA is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IQVIA	10 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Icon	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

IQVIA beats Icon on 14 of the 17 factors compared between the two stocks.

How does IQVIA compare to Medpace?

IQVIA (NYSE:IQV) and Medpace (NASDAQ:MEDP) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk, earnings and dividends.

IQVIA presently has a consensus target price of $225.69, indicating a potential upside of 32.23%. Medpace has a consensus target price of $467.08, indicating a potential upside of 11.43%. Given IQVIA's stronger consensus rating and higher probable upside, research analysts clearly believe IQVIA is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IQVIA	0 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	3.00
Medpace	1 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20

IQVIA has higher revenue and earnings than Medpace. IQVIA is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IQVIA	$16.63B	1.71	$1.36B	$8.07	21.15
Medpace	$2.68B	4.47	$451.12M	$15.91	26.35

89.6% of IQVIA shares are owned by institutional investors. Comparatively, 78.0% of Medpace shares are owned by institutional investors. 1.7% of IQVIA shares are owned by insiders. Comparatively, 20.5% of Medpace shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Medpace has a net margin of 17.19% compared to IQVIA's net margin of 8.33%. Medpace's return on equity of 120.89% beat IQVIA's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IQVIA	8.33%	30.50%	6.53%
Medpace	17.19%	120.89%	24.79%

IQVIA has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market. Comparatively, Medpace has a beta of 1.19, suggesting that its stock price is 19% more volatile than the broader market.

In the previous week, Medpace had 13 more articles in the media than IQVIA. MarketBeat recorded 31 mentions for Medpace and 18 mentions for IQVIA. IQVIA's average media sentiment score of 0.98 beat Medpace's score of 0.21 indicating that IQVIA is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IQVIA	10 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Medpace	4 Very Positive mention(s)	0 Positive mention(s)	25 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Medpace beats IQVIA on 9 of the 17 factors compared between the two stocks.

How does IQVIA compare to Bio-Techne?

IQVIA (NYSE:IQV) and Bio-Techne (NASDAQ:TECH) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.

89.6% of IQVIA shares are owned by institutional investors. Comparatively, 98.9% of Bio-Techne shares are owned by institutional investors. 1.7% of IQVIA shares are owned by company insiders. Comparatively, 1.3% of Bio-Techne shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

IQVIA has a beta of 1.18, indicating that its share price is 18% more volatile than the broader market. Comparatively, Bio-Techne has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market.

IQVIA presently has a consensus target price of $225.69, indicating a potential upside of 32.23%. Bio-Techne has a consensus target price of $66.77, indicating a potential upside of 49.24%. Given Bio-Techne's higher possible upside, analysts clearly believe Bio-Techne is more favorable than IQVIA.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IQVIA	0 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	3.00
Bio-Techne	0 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.79

Bio-Techne has a net margin of 9.05% compared to IQVIA's net margin of 8.33%. IQVIA's return on equity of 30.50% beat Bio-Techne's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IQVIA	8.33%	30.50%	6.53%
Bio-Techne	9.05%	13.57%	10.66%

IQVIA has higher revenue and earnings than Bio-Techne. IQVIA is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IQVIA	$16.63B	1.71	$1.36B	$8.07	21.15
Bio-Techne	$1.21B	5.79	$73.40M	$0.69	64.84

In the previous week, IQVIA had 1 more articles in the media than Bio-Techne. MarketBeat recorded 18 mentions for IQVIA and 17 mentions for Bio-Techne. IQVIA's average media sentiment score of 0.98 beat Bio-Techne's score of 0.23 indicating that IQVIA is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IQVIA	10 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Bio-Techne	3 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

IQVIA beats Bio-Techne on 10 of the 17 factors compared between the two stocks.

How does IQVIA compare to Agilent Technologies?

Agilent Technologies (NYSE:A) and IQVIA (NYSE:IQV) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings, dividends and media sentiment.

Agilent Technologies has a net margin of 18.26% compared to IQVIA's net margin of 8.33%. IQVIA's return on equity of 30.50% beat Agilent Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agilent Technologies	18.26%	24.49%	12.83%
IQVIA	8.33%	30.50%	6.53%

89.6% of IQVIA shares are owned by institutional investors. 1.7% of IQVIA shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, IQVIA had 11 more articles in the media than Agilent Technologies. MarketBeat recorded 18 mentions for IQVIA and 7 mentions for Agilent Technologies. IQVIA's average media sentiment score of 0.98 beat Agilent Technologies' score of 0.83 indicating that IQVIA is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agilent Technologies	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
IQVIA	10 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Agilent Technologies presently has a consensus price target of $163.71, indicating a potential upside of 44.59%. IQVIA has a consensus price target of $225.69, indicating a potential upside of 32.23%. Given Agilent Technologies' higher possible upside, research analysts clearly believe Agilent Technologies is more favorable than IQVIA.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agilent Technologies	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00
IQVIA	0 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	3.00

IQVIA has higher revenue and earnings than Agilent Technologies. IQVIA is trading at a lower price-to-earnings ratio than Agilent Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agilent Technologies	$6.95B	4.61	$1.30B	$4.53	24.99
IQVIA	$16.63B	1.71	$1.36B	$8.07	21.15

Agilent Technologies has a beta of 1.22, meaning that its share price is 22% more volatile than the broader market. Comparatively, IQVIA has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market.

Summary

IQVIA beats Agilent Technologies on 9 of the 15 factors compared between the two stocks.

Get IQVIA News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IQV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IQV vs. The Competition

Export

Metric	IQVIA	MED INSTRUMENTS Industry	Medical Sector	NYSE Exchange
Market Cap	$28.49B	$6.69B	$6.29B	$23.00B
Dividend Yield	N/A	1.72%	2.79%	4.07%
P/E Ratio	21.15	49.59	20.87	28.39
Price / Sales	1.71	43.34	521.62	39.21
Price / Cash	9.80	24.21	42.94	25.11
Price / Book	4.49	6.50	9.86	4.76
Net Income	$1.36B	$158.34M	$3.55B	$1.06B
7 Day Performance	-4.62%	-2.32%	-0.26%	-0.74%
1 Month Performance	-2.66%	-1.73%	1.39%	1.74%
1 Year Performance	20.19%	-1.67%	41.07%	25.05%

IQVIA Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IQV IQVIA	4.4615 of 5 stars	$170.68 -1.0%	$225.69 +32.2%	+14.2%	$28.49B	$16.63B	21.15	93,000	Buyback Announcement
BRKR Bruker	2.9009 of 5 stars	$43.27 -2.0%	$50.54 +16.8%	+13.2%	$6.72B	$3.44B	N/A	11,085	Analyst Downgrade
ICLR Icon	4.5223 of 5 stars	$118.96 -4.4%	$149.38 +25.6%	-16.4%	$10.05B	$8.28B	16.10	41,900
MEDP Medpace	3.1684 of 5 stars	$417.29 -1.6%	$467.08 +11.9%	+36.6%	$12.11B	$2.53B	26.23	6,200
TECH Bio-Techne	3.7557 of 5 stars	$47.42 -1.9%	$66.77 +40.8%	-13.0%	$7.57B	$1.22B	68.73	3,100

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:IQV) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IQVIA (IQV) Competitors